UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
9.04 x 2 25.97 x 1
Pre-market by (Cboe BZX)
22.60 -1.44 (-5.99%) 04/01/25 [NYSE]
9.04 x 2 25.97 x 1
Pre-market 21.52 -1.08 (-4.78%) 04:07 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
21.47
Day High
26.48
Open 26.48
Previous Close 24.04 24.04
Volume 2,087,900 2,087,900
Avg Vol 1,210,255 1,210,255
Stochastic %K 20.51% 20.51%
Weighted Alpha -62.05 -62.05
5-Day Change -7.27 (-24.34%) -7.27 (-24.34%)
52-Week Range 21.47 - 55.72 21.47 - 55.72
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,453,643
  • Shares Outstanding, K 102,065
  • Annual Sales, $ 0 K
  • Annual Income, $ -846,420 K
  • EBIT $ -885 M
  • EBITDA $ -877 M
  • 60-Month Beta 1.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.60

Options Overview Details

View History
  • Implied Volatility 106.39% ( +7.30%)
  • Historical Volatility 76.40%
  • IV Percentile 76%
  • IV Rank 62.10%
  • IV High 138.64% on 05/24/24
  • IV Low 53.57% on 08/16/24
  • Put/Call Vol Ratio 0.10
  • Today's Volume 3,566
  • Volume Avg (30-Day) 826
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 18,308
  • Open Int (30-Day) 15,291

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.64
  • Number of Estimates 9
  • High Estimate -1.30
  • Low Estimate -1.92
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +25.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.47 +5.26%
on 03/31/25
Period Open: 37.18
36.95 -38.84%
on 03/03/25
-14.58 (-39.21%)
since 02/28/25
3-Month
21.47 +5.26%
on 03/31/25
Period Open: 37.35
44.28 -48.96%
on 02/11/25
-14.75 (-39.49%)
since 12/31/24
52-Week
21.47 +5.26%
on 03/31/25
Period Open: 52.06
55.72 -59.44%
on 04/04/24
-29.46 (-56.59%)
since 04/01/24

Most Recent Stories

More News
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

BHVN : 22.60 (-5.99%)
COLL : 29.39 (-1.54%)
TRVI : 6.01 (-4.45%)
AVTX : 6.85 (-14.48%)
Company News for Mar 4, 2025

California Resources Corp.’s (CRC) shares plummeted 11.7% after posting fourth-quarter 2024 adjusted earnings per share of $0.91, missing the Zacks Consensus Estimate of $0.34.Shares of TG Therapeutics...

TGTX : 37.75 (-4.26%)
BHVN : 22.60 (-5.99%)
CRC : 45.31 (+3.05%)
NOMD : 19.65 (unch)
Why Biohaven Stock Triumphed on Tuesday

News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is...

BHVN : 22.60 (-5.99%)
Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

BHVN : 22.60 (-5.99%)
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely

Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients.

BHVN : 22.60 (-5.99%)
VTI : 275.77 (+0.34%)
SRRK : 30.06 (-6.50%)
IWM : 199.51 (+0.01%)
XBI : 78.16 (-3.63%)
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 22.60 (-5.99%)
ANIP : 68.02 (+1.60%)
CPRX : 23.92 (-1.36%)
SRRK : 30.06 (-6.50%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 22.60 (-5.99%)
KRYS : 174.58 (-3.17%)
FULC : 2.76 (-4.17%)
ANIP : 68.02 (+1.60%)
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

BHVN : 22.60 (-5.99%)
Canada Jobs in Focus Next Week

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 484.74 (-0.02%)
MCHP : 48.50 (+0.19%)
PLTR : 84.68 (+0.33%)
DIS : 97.68 (-1.03%)
ANET : 78.49 (+1.30%)
TM : 174.42 (-1.20%)
UBER : 72.99 (+0.18%)
ABNB : 121.18 (+1.44%)
HMC : 26.80 (-1.22%)
CEG : 206.94 (+2.63%)
RBLX : 60.99 (+4.63%)
BHVN : 22.60 (-5.99%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 22.60 (-5.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 26.51
2nd Resistance Point 25.36
1st Resistance Point 23.98
Last Price 22.60
1st Support Level 21.45
2nd Support Level 20.30
3rd Support Level 18.92

See More

52-Week High 55.72
Fibonacci 61.8% 42.64
Fibonacci 50% 38.60
Fibonacci 38.2% 34.55
Last Price 22.60
52-Week Low 21.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies